Tokyo Tape
Sign in
← Toho Holdings

Quarterly report · Q2

8129.TEDINET S100S94E
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥734.8bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥1.39T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥681.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥6.5bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥5.8bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥7.9bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥19.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥7.4bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥13.0bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥6.0bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.6bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥8.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥3.6bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥801.4bnat 2023-09-30Cons.Assets
Total assets¥715.3bnat 2023-03-31Cons.Assets
Total assets¥740.6bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥556.2bnat 2023-09-30Cons.Liabilities
Total liabilities¥472.4bnat 2023-03-31Cons.Liabilities
Net assets / equity¥245.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥242.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥245.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥137.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥86.2bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥133.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥81.8bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥97.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.0bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥53.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥9m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥3.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥4.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥407m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥13.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥134.192023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥112.262023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥196.72022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥51.012022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥121.192023-04-01 → 2023-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥180.672022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥46.882022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio30.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio33.9%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥29.3bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥46.6bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥895m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2023-04-01 → 2023-09-30¥5.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥4.0bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2023-04-01 → 2023-09-30¥436m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2023-04-01 → 2023-09-30¥709.4bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2023-04-01 → 2023-09-30¥684.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥24.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥678m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥764.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥734.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥29.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥8.3bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥28.3bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥850m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue external2022-04-01 → 2022-09-30¥45.1bn
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segmentsegment profit2022-04-01 → 2022-09-30¥878m
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue2022-04-01 → 2022-09-30¥4.8bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.7bn
jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segmentsegment profit2022-04-01 → 2022-09-30¥478m
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue2022-04-01 → 2022-09-30¥656.6bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue external2022-04-01 → 2022-09-30¥632.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥23.8bn
jpcrp040300-q2r_E02608-000Medical Products Retailreportable segmentsegment profit2022-04-01 → 2022-09-30¥5.1bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥3.3bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.5bn
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥782m
jpcrp040300-q2r_E02608-000Other Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥246m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥709.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥681.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥28.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥6.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 581
ItemContextValueUnit
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所プライム市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数は100株であります。
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口)
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)東京都港区浜松町２－11－３
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)塩野義製薬株式会社
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)大阪府大阪市中央区道修町３－１－８
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)株式会社日本カストディ銀行（信託口）
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)東京都中央区晴海１－８－12
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)みずほ信託銀行株式会社　退職給付信託　第一三共口　再信託受託者　株式会社日本カストディ銀行
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)東京都中央区晴海１－８－12
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)東邦ホールディングス従業員持株会
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)東京都世田谷区代沢５－２－１
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)河野　博行
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)広島県広島市安佐南区
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)ＣＧＭＬ　ＰＢ　ＣＬＩＥＮＴ　ＡＣＣＯＵＮＴ／ＣＯＬＬＡＴＥＲＡＬ（常任代理人　シティバンク、エヌ・エイ東京支店）
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)モルガン・スタンレーＭＵＦＧ証券株式会社
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)東京都千代田区大手町１－９－７
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesReciprocalHoldingSharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember
Original text (Japanese)１単元(100株)未満の株式
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)提出会社
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)東京都世田谷区代沢５－２－１
Name of shareholder treasury shares etcCurrentQuarterInstant_Row2Member
Original text (Japanese)酒井薬品株式会社
Address of shareholder treasury shares etcCurrentQuarterInstant_Row2Member
Original text (Japanese)東京都三鷹市野崎１－11－22
Name of shareholder treasury shares etcCurrentQuarterInstant_Row3Member
Original text (Japanese)株式会社ヤマトメディカル

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass